主要研究目的：研究空腹和餐后状态下单次口服受试制剂聚普瑞锌颗粒（规格：0.5 g:75 mg，持证商：吉林省博大伟业制药有限公司）与参比制剂聚普瑞锌颗粒（Promac®，规格：0.5 g:75 mg，持证商：ゼリア新薬工業株式会社）在健康受试者体内的药代动力学，评价空腹和餐后状态口服两种制剂的生物等效性。

开始日期2023-05-18

申办/合作机构

吉林省博大伟业制药有限公司

100 项与聚普瑞锌相关的临床结果

登录后查看更多信息

100 项与聚普瑞锌相关的转化医学

登录后查看更多信息

100 项与聚普瑞锌相关的专利（医药）

登录后查看更多信息

522

项与聚普瑞锌相关的文献（医药）

2025-01-01·Current medicinal chemistry

The Possible Roles of β-alanine and L-carnosine in Anti-aging

Article

作者: Lysiuk, Roman ; Piscopo, Salva ; Shanaida, Mariia ; Résimont, Stéphane ; Shanaida, Volodymyr ; Dzyha, Svitlana ; Mujawdiya, Pavan Kumar ; Bjørklund, Geir ; Peana, Massimiliano ; Gasmi, Amin ; Beley, Nataliya ; Smetanina, Kateryna

β-alanine (BA), being a non-proteinogenic amino acid, is an important constituent of L-carnosine (LC), which is necessary for maintaining the muscle buffering capacity and preventing a loss of muscle mass associated with aging effects. BA is also very important for normal human metabolism due to the formation of a part of pantothenate, which is incorporated into coenzyme A. BA is synthesized in the liver, and its combination with histidine results in the formation of LC, which accumulates in the muscles and brain tissues and has a well-defined physiological role as a good buffer for the pH range of muscles that caused its rapidly increased popularity as ergogenic support to sports performance. The main antioxidant mechanisms of LC include reactive oxygen species (ROS) scavenging and chelation of metal ions. With age, the buffering capacity of muscles also declines due to reduced concentration of LC and sarcopenia. Moreover, LC acts as an antiglycation agent, ultimately reducing the development of degenerative diseases. LC has an anti-inflammatory effect in autoimmune diseases such as osteoarthritis. As histidine is always present in the human body in higher concentrations than BA, humans have to get BA from dietary sources to support the required amount of this critical constituent to supply the necessary amount of LC synthesis. Also, BA has other beneficial effects, such as preventing skin aging and intestinal damage, improving the stress-- fighting capability of the muscle cells, and managing an age-related decline in memory and learning. In this review, the results of a detailed analysis of the role and various beneficial properties of BA and LC from the anti-aging perspective are presented.

2024-05-01·Photochemistry and photobiology

Evaluation of human skin response to solar‐simulated radiation in an ex vivo model: Effects and photoprotection of L‐Carnosine

Article

作者: Girardi, Cristina ; Benato, Francesca ; Stuhlmann, Dominik ; Massironi, Marco ; Massironi, Michele ; Vindigni, Vincenzo

Abstract:

Sunlight, and more specifically the UV component, induces several skin damages, including sunburns, erythema and photoaging. The purpose of this work is to set up an ex vivo human skin model to assess the capacity of active principles in protecting skin from the deleterious effects of solar radiation. Ex vivo human skin biopsies were cultured in an air–liquid interface and exposed to solar‐simulated radiation (SSR, 300–750 nm). L‐Carnosine (0.2% and 2%) was applied topically to be tested as photoprotective compound. The effect on oxidative stress induction, photoaging and skin transcriptional profile was assessed by evaluating reactive oxygen species, advanced glycosylation end products formation and gene expression changes. In our model, SSR increases ROS production and AGE accumulation and affects the expression of genes related to oxidative stress, pigmentation, immunity, inflammation and photoaging. Among these pathways, 11 genes were selected as biomarkers to evaluate the skin solar radiation response. Results showed that L‐Carnosine provides effective prevention against solar radiation damages reducing ROS, AGEs and mitigating the modulation of the selected biomarker genes. In conclusion, we report that our ex vivo skin model is a valuable system to assess the consequences of solar light exposure and the capacity of topically applied L‐Carnosine to counteract them.

2024-04-01·International journal of pharmaceutics

Magnetic Lipid-Based hybrid nanosystems: A combined stimuli- responsive nanocarriers for enriched chemotherapeutic potential of L-carnosine in induced breast Ehrlich ascites tumor model

Article

作者: Abdallah, Ossama Y ; Farid, Ragwa M ; M E Gaafar, Passent ; Helmy, Maged W ; Hazzah, Heba A ; AbouKilila, HussamElDin Y

Magnetic Lipid-Based Hybrid Nanosystems (M-LC_NPs) is a novel nanoplatform that can respond to magnetic stimulus and are designed for delivering L-carnosine (CN), a challenging dipeptide employed in the treatment of breast cancer. CN exhibits considerable water solubility and undergoes in-vivo degradation, hence restricting its application. Consequently, it is anticipated that the developed M-LC_NPs will enhance the effectiveness of CN. To ensure the physical stability of MNPs, they were initially coated with a mixture of oleic acid and oleylamine before being included in pegylated liquid crystalline nanoparticles (PLCNPs). The proposed M-LC_NPs exhibited promising in-vitro characteristics, notably a small particle size (143.5 nm ± 1.25) and a high zeta potential (-39.5 mV ± 1.54), together with superparamagnetic behavior. The in-vitro release profile exhibited a prolonged release pattern. The IC₅₀ values of M-LC_NPs were 1.57 and 1.59 times lower than these of the CN solution after 24 and 48 hours, respectively. Female BALB/C female mice with an induced breast cancer (Ehrlich Ascites tumor [EAT] model) were used to study the influence of an external magnetic field on the chemotherapeutic activity and toxicity of CN loaded in the developed M-LC_NPs. Stimuli-responsive M-LCNPs exhibited no apparent systemic toxicity in addition to enhanced chemotherapeutic efficacy compared to nontargeted M-LC_NPs and CN solution, as evidenced by a reduction of % tumor growth (11.7%), VEGF levels (22.95 pg/g tissue), and cyclin D1 levels (27.61 ng/g tissue), and an increase in caspase-3 level (28.9 ng/g tissue). Ultimately, the developed stimuli-responsive CN loaded M-LC_NPs presented a promising nanoplatform for breast cancer therapy.

项与聚普瑞锌相关的新闻（医药）

2023-11-20

·米内网

海思科发威了！15款1类新药曝光，猛攻3大千亿市场，4款创新药上市可期

精彩内容第九批集采结果出炉，海思科注射用醋酸卡泊芬净中选。今年以来海思科研发进展不断：4款创新药申报NDA，8款1类新药申报IND，6个品种过评……今年前三季度公司研发费用3.42亿元，同比增长23.19%。目前公司有16款创新药处于申报临床及以上阶段，麻醉新药美国Ⅲ期临床推进中，3款1类新药上市可期。麻醉新药半年暴涨270%！4款创新药申报NDA海思科成立于2000年，拥有覆盖麻醉产品、肠外营养系、肿瘤止吐、肝胆消化、抗生素、心脑血管等多个细分领域的产品布局。近年来公司以“创新”为内核，不断加大研发投入力度，2022年研发投入9.58亿元，同比增长17.57%；2023年前三季度研发费用3.42亿元，同比增长23.19%。首款1类新药环泊酚注射液于2020年12月获批上市，为中国首个具有自主知识产权的1类静脉麻醉药。目前，环泊酚注射液已有3项适应症“非气管插管手术/操作中的镇静和麻醉”、“全身麻醉诱导和维持”、“重症监护期间的镇静”在中国获批上市，全麻诱导适应症正在美国开展Ⅲ期临床试验，预计2024年递交NDA申请。随着医保目录常态化调整，环泊酚注射液于2021年11月通过谈判进入国家医保目录。借助医保放量机会，环泊酚注射液2022年以4.35亿元的销售收入创造了国内创新药上市阶段的业绩新高。米内网数据显示，2023年上半年重点省市公立医院终端环泊酚注射液市场增速达270.11%，已超过2022年全年。重点省市公立医院终端环泊酚注射液销售情况（单位：万元）来源：米内网重点省市公立医院药品终端竞争格局今年以来，海思科已有3款1类新药提交上市申请。其中，HSK16149胶囊是一款口服γ-氨基丁酸（GABA）类似物，已报产适应症包括糖尿病周围神经痛、带状疱疹后神经痛；HSK7653片是一款长效DPP-4抑制剂，用于治疗2型糖尿病；HSK21542注射液是一款强效外周kappa阿片受体选择性激动剂，用于腹部手术术后镇痛。此外，公司引进的5.1类新药利鲁唑口溶膜已于2023年5月提交上市申请，用于治疗肌萎缩侧索硬化症。海思科待批创新药15款1类新药在研，猛攻3大千亿市场除了4款创新药申报NDA，今年以来海思科还有8款1类新药申报IND，其中6款1类新药HSK40118片、HSK37251片、HSK38008干混悬剂、HSK31679片、HSK34890片、HSK21542片的临床试验申请已获得批准。目前海思科累计有15类1类新药处于申报临床及以上阶段，均为小分子化学创新药。公司创新管线注重差异化布局，聚焦于围手术期、肿瘤、代谢、呼吸等疾病领域，覆盖了GABAA、kappa、DPP-4、THR-β、BTK、EGFR、DDP1等疾病靶点。海思科主要在研1类新药米内网数据显示，2022年中国城市公立医院、县级公立医院、城市社区中心及乡镇卫生院（简称中国公立医疗机构）终端抗肿瘤和免疫调节剂、消化系统及代谢药销售额均超过1500亿元，神经系统药物销售额接近1000亿元。神经系统领域中，海思科已公开的1类新药有5款。其中，环泊酚注射液已在中国获批上市，美国Ⅲ期临床推进中；HSK16149胶囊、HSK21542注射液NDA在审中，有望于2024年获批上市；HSK21542片处于Ⅰ期临床阶段，HSK36357胶囊已申报IND。消化代谢领域中，HSK7653片是首款每两周服用1次的口服DPP-4抑制剂，有望于2024年获批上市；HSK31679片、HSK34890片临床试验推进中。肿瘤领域中，3款Protac新药HSK29116散（治疗难治性B细胞淋巴瘤）、HSK40118片（治疗晚期非小细胞肺癌）、HSK38008干混悬剂（治疗前列腺癌）均处于Ⅰ期临床阶段；HSK37251片（拟用于恶性实体瘤）已获批临床。随着创新管线快速推进，海思科创新药将逐步迎来上市收获期，不断扩充公司产品线。仿制药管线收缩！中标23亿注射剂国采仿制药方面，今年以来海思科已有一个品种利丙双卡因乳膏获批上市，为国产第2家+首家过评；5个品种富马酸卢帕他定片、磺达肝癸钠注射液、复方氨基酸注射液（18AA-Ⅶ）、注射用醋酸卡泊芬净、复方氨基酸注射液(18AA-IX)通过仿制药一致性评价。截至目前，海思科已有28个品种通过/视同通过一致性评价。其中，15个品种为国内首家过评，精氨酸谷氨酸注射液、聚普瑞锌颗粒、复方氨基酸(18AA)/葡萄糖(15%)电解质注射液、复方氨基酸注射液(18AA-Ⅸ)等4个品种为独家过评。11月16日，国家组织药品联合采购办公室发布公告，正式公布第九批国家组织药品集采中选的41种药品和价格，中选结果将于2024年3月实施。此次海思科有一个品种注射用醋酸卡泊芬净获得中选资格，价格为132元（50mg*1瓶/盒），供应省份为北京、河北、浙江、宁夏、新疆（含兵团）。中国公立医疗机构终端注射用醋酸卡泊芬净销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局注射用醋酸卡泊芬净是第一个新一代棘白菌素类广谱抗真菌药物，海思科该产品于2023年2月过评。米内网数据显示，2022年中国公立医疗机构终端注射用醋酸卡泊芬净销售额超过23亿元，海思科市场份额为1.21%。借助国采放量机会，公司该产品有望提高市场占有率。不难发现，海思科仿制药管线明显收缩。2023年至今，公司只提交了注射用水溶性维生素一款仿制药的上市申请。目前，海思科仅有4个仿制药复方维生素注射液(3)、格列齐特缓释片、地奈德乳膏、注射用水溶性维生素上市申请在审中，获批生产后将视同通过一致性评价。公司持续聚焦创新药物研发，除商业化阶段产品及临床研究项目外，海思科约有30个项目处于筛选阶段，涉及肿瘤、自免、呼吸和眼科等治疗领域，未来将有多个项目申报IND。数据来源：米内网数据库注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；米内网重点省市公立医院化学药终端竞争格局数据库是以20+省市，近700家样本省市公立医院的化学药采购数据为基础，对化学药全品类进行连续监测的样本省市样本医院数据库；上述销售额以产品在终端的平均零售价计算。本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092●温馨提示●因为微信公众号修改了推送规则，最近很多读者反映没有及时看到推文。把米内网设为“星标”，就能每天与我们不见不散啦，具体操作如下：【分享、点赞、在看】点一点不失联哦

临床3期申请上市临床申请

2023-10-26

·PRNewswire

Serious Concerns About Frequent Heartburn Medications Spurs Demand for Healthy Alternatives

-Enzymedica Offers All-Natural Relief- VENICE, Fla., Oct. 26, 2023 /PRNewswire/ -- As consumer interest in heartburn solutions reaches unprecedented levels, Enzymedica, a trusted leader in digestive health, introduces a range of all-natural, healthy alternatives for occasional heartburn and indigestion relief. This move comes in response to the recent revelation of a study linking long-term usage of Proton Pump Inhibitors (PPIs) to potential health risks, including dementia. With a commitment to providing safe and effective solutions, Enzymedica offers consumers a variety of options that not only relieve symptoms of occasional heartburn resulting from food and diet choices, but also promote overall digestive wellness. Continue Reading Concerns about heartburn medication spurs demand for healthy alternatives for occasional heartburn relief like Enzymedica's Heartburn Soothe. (PRNewsfoto/Enzymedica) The heartburn solutions category has faced stagnation due to a lack of innovation, concerns about drug side effects and confusion surrounding the frequent, long-term usage of PPIs and other acid inhibitors. The recent study shedding light on potential health risks associated with PPIs has left consumers seeking trustworthy alternatives that prioritize their well-being. Not only do Enzymedica's range of heartburn relief products, including Heartburn Soothe, Acid Soothe and Betaine HCI, offer instant relief from occasional heartburn and indigestion, but they also contribute to the rebuilding of the gastrointestinal lining and promote long-term digestive health. "It is disheartening and concerning to hear about the results of this latest study linking heartburn medications and dementia, especially considering there are so many people using them on a long-term basis - far longer than indicated. The good news is that there are all-natural, safe solutions to help people with occasional indigestion and heartburn," says Ryan Sensenbrenner, senior director of marketing at Enzymedica. "In addition to food, diet and lifestyle choices, some great suggestions for relieving occasional heartburn include looking for products that include betaine, zinc carnosine and/or alginate, like Enzymedica's entire suite of products indicated to provide instant relief to soothe and protect the digestive system." Enzymedica products are available for purchase on their official website, Enzymedica.com, as well as Amazon.com and at various retail locations such as Whole Foods, Sprouts, Fresh Thyme and CVS. These products offer consumers a reliable and convenient way to address their occasional heartburn concerns with natural, science-backed solutions. About Enzymedica: Enzymedica is a trusted leader in the field of digestive health, committed to providing natural, effective solutions for various digestive concerns. With a focus on innovation and science-backed formulations, Enzymedica offers consumers a wide range of products that promote optimal digestive wellness. Disclaimer: The statements made in this press release have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. Media Contact Anjie Oberholzer (484) 241-6926 [email protected] SOURCE Enzymedica

2023-08-07

·米内网

海思科爆发了！独家品种暴涨764%，11款1类新药来势汹汹，2大注射剂备战国采

精彩内容今年以来海思科研发进展不断：长效降糖药HSK7653片申报NDA，6款1类新药申报IND，6个品种过评……目前海思科进入临床阶段的1类新药主要有12款，3款1类新药上市可期；静脉麻醉新药持续放量，驱动公司业绩增长；28个品种过评（14个首家），2大品种备战第九批集采。20款创新药在研，3款1类新药上市可期今年1月，海思科的长效DPP-4抑制剂HSK7653片NDA获受理，HSK40118片、HSK38008干混悬剂、HSK37251片IND获受理；3月，HSK31679片Ⅱ期临床试验获批，HSK40118片Ⅰ期临床试验首例受试者入组；6月，HSK34890片、HSK21542片IND获受理，2款内分泌创新药研究成果ADA大会发布。在创新药领域多年来的默默耕耘，海思科于2022年迎来创新药营销元年，1类新药环泊酚注射液实现销售收入4.35亿元；进入2023年公司创新药研发持续推进，目前已有长效降糖药HSK7653片申报NDA、6款1类新药申报IND、4款1类新药获批临床。目前海思科在研创新药有20款，其中进入临床阶段的1类创新药主要有12款，均为小分子化学创新药，涵盖消化道及代谢、神经系统、肿瘤系统、血液和造血系统、呼吸系统等治疗领域，涉及DPP-4、THR-β、BTK、EGFR、DDP1等靶点。海思科主要在研1类新药除了已获批上市的环泊酚注射液，α2δ-1调节剂HSK16149胶囊（治疗糖尿病周围神经痛）已于2022年10月申报NDA，其带状疱疹后神经痛适应症处于Ⅲ期临床阶段、辅助镇痛适应症处于Ⅱ期临床阶段；DPP-4抑制剂HSK7653片（治疗2型糖尿病）已于2023年1月申报NDA；kappa受体HSK21542注射液治疗术后镇痛和慢性肾病瘙痒适应症均处于Ⅲ期临床阶段，2024年公司有望集齐4款创新药。HSK16149胶囊、HSK21542注射液均属于神经系统药物，HSK7653片属于内分泌系统药物。米内网数据显示，2022年中国城市公立医院、县级公立医院、城市社区中心及乡镇卫生院（简称中国公立医疗机构）终端消化系统及代谢药销售额超过1600亿元，神经系统药物销售额接近1000亿元。28个品种过评！2大注射剂备战第九批集采7月23日、8月1日，海思科相继发布公告称，公司的磺达肝癸钠注射液、富马酸卢帕他定片通过仿制药一致性评价，有利于提高产品竞争力，带来新的市场机会。富马酸卢帕他定片是一种长效抗组胺剂，通过选择性拮抗组胺H1受体发挥作用，主要用于12岁以上成人和青少年过敏性鼻炎和荨麻疹的对症治疗。米内网数据显示，2022年中国公立医疗机构终端富马酸卢帕他定片销售额超过3亿元。海思科为该产品第2家过评企业。磺达肝癸钠注射液是针对凝血X因子的一种新型的人工合成抗凝剂，具有生物利用度高、起效快、半衰期长等优点。米内网数据显示，2022年中国公立医疗机构终端磺达肝癸销售额超过5亿元。目前，海思科已有替格瑞洛片、磺达肝癸钠注射液2款抗血栓药过评。今年以来，海思科已有5个品种通过仿制药一致性评价，包括富马酸卢帕他定片、磺达肝癸钠注射液、复方氨基酸注射液（18AA-Ⅶ）、注射用醋酸卡泊芬净、复方氨基酸注射液(18AA-IX)。此外，利丙双卡因乳膏国产第2家获批上市，视同过评。海思科通过/视同通过一致性评价品种截至目前，海思科已有28个品种通过/视同通过一致性评价。其中，14个品种为国内首家过评，复方氨基酸注射液(18AA-Ⅶ)、精氨酸谷氨酸注射液、聚普瑞锌颗粒、复方氨基酸注射液(18AA-Ⅸ)等5个品种为独家过评。海思科暂未纳入集采且已满足5家及以上的品种28个过评品种中，14个品种已纳入国家集采，海思科累计有8个品种中选；14个品种暂未纳入国家集采，其中2个品种注射用盐酸头孢替安、注射用醋酸卡泊芬净已满足5家及以上的入围条件。米内网数据显示，2022年中国公立医疗机构终端注射用醋酸卡泊芬净销售额超过23亿元，注射用盐酸头孢替安销售额超过7亿元。2款注射剂分别已有7家、11家企业过评，大概率将纳入第九批集采。创新药销售暴涨！上半年净利预增7月13日，海思科发布业绩预告，预计上半年净利7200万元-8000万元，同比增长3.12%-14.58%。报告期内，公司创新药产品环泊酚注射液的销售同比大幅增加，对业绩有较好拉动；公司二季度营业收入、净利润及扣非净利润环比一季度均有较大幅度增长。公司首款1类新药环泊酚注射液于2020年12月获批上市，为中国首个具有自主知识产权的1类静脉麻醉药；2021年11月获纳入国家医保目录，2022年以4.35亿元的销售收入创造了国内创新药上市阶段的业绩新高。米内网数据显示，2022年中国公立医疗机构终端环泊酚注射液销售额较上年同期增长764.46%。中国公立医疗机构终端环泊酚注射液销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局环泊酚注射液上市两年已在国内进入约1300家医院，在中国已获批3项适应症：非气管插管的手术/操作中的镇静和麻醉、全身麻醉诱导和维持、ICU镇静；国际化进程持续推进，全麻诱导适应症美国Ⅲ期临床开展中。随着创新药开始成为业绩增长的驱动力，海思科也持续加大研发投入力度，2022年研发投入9.58亿元，同比增长17.57%。通过持续不断的创新，公司已拥有具有自主知识产权的多种前沿药物技术，并形成了丰富的管线项目储备。除了自主研发，海思科也积极从外部引进创新药产品，如引进美国Starton用于肿瘤化疗所致呕吐的奥氮平透皮贴剂、美国Biosplice长效治疗骨关节炎的Lorecivivint、美国Aquestive治疗“渐冻症”的利鲁唑口腔膜。其中，利鲁唑口腔膜NDA于今年5月获得受理，若顺利获批将进一步扩充公司产品线。资料来源：米内网数据库、公司公告注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092●温馨提示●因为微信公众号修改了推送规则，最近很多读者反映没有及时看到推文。把米内网设为“星标”，就能每天与我们不见不散啦，具体操作如下：【分享、点赞、在看】点一点不失联哦

临床申请申请上市一致性评价临床2期临床3期

100 项与聚普瑞锌相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01611	聚普瑞锌	A02B	DB09221

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
胃溃疡	日本	Zeria Pharmaceutical Co., Ltd.	1994-10-06

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


Pubmed 人工标引	N/A	胃溃疡	224	Polaprezinc	鹹窪獵膚壓繭獵膚齋觸(糧範獵繭淵鹽壓艱顧簾) = 顧窪餘餘繭築壓選艱窪醖遞鹹廠醖齋齋鑰築窪 (憲窪構壓願鑰艱襯鑰鹹 ) 更多	不佳	2022-08-12
				Rebamipide	鹹窪獵膚壓繭獵膚齋觸(糧範獵繭淵鹽壓艱顧簾) = 蓋鑰觸鏇膚鏇簾網獵顧醖遞鹹廠醖齋齋鑰築窪 (憲窪構壓願鑰艱襯鑰鹹 ) 更多
NCT00810368 (CTgov)	临床2期	波斯湾综合症	33	Carnosine (Carnosine Treatment Group)	鬱夢夢製齋製鬱範蓋廠(網願餘壓蓋夢鑰鏇窪繭) = 選簾膚夢襯獵積構獵獵遞願衊製網築製鏇蓋繭 (願艱淵壓淵淵蓋願廠衊, 醖蓋衊觸製製鹽憲醖鏇 ~ 鬱鏇鏇製鏇膚衊鹹繭網) 更多	-	2016-08-18
				Placebo (Placebo Control Group)	鬱夢夢製齋製鬱範蓋廠(網願餘壓蓋夢鑰鏇窪繭) = 選積範夢憲網鹽構鑰淵遞願衊製網築製鏇蓋繭 (願艱淵壓淵淵蓋願廠衊, 窪糧蓋願積壓選淵齋範 ~ 願繭醖簾選壓廠糧選廠) 更多
ASTRO2015	N/A	放射性皮炎	-	PZ before irradiation	淵築蓋製範鹹醖選淵壓(蓋遞夢襯觸淵鹽製範顧) = 糧築壓遞願糧齋廠鏇簾觸壓糧鏇鹽鏇鏇獵壓顧 (窪淵淵遞觸膚壓築膚繭, 12.5 ~ 26.5) 更多	积极	2015-11-01
				PZ after irradiation	網遞廠觸艱遞壓艱餘鏇(鹹範簾蓋襯遞願獵醖願) = 鹹觸鹹淵衊選範鬱鬱鬱衊襯膚顧鬱遞糧製範製 (網積觸遞願壓廠積夢鏇 )